Natco Pharma宣布将其对美国生物技术公司eGenesis Inc.的拟议投资额从此前公布的1400万美元增加到1670万美元。这一消息于9月28日（星期一）在公司的公开文件中公布。该投资将通过Natco Pharma的全资子公司Natco Pharma Inc.和Natco Pharma USA LLC进行，投资方式是通过年利率为8%（每年复利）的可转换本票来完成。
Natco Pharma has increased its proposed investment in US-based biotechnology company eGenesis Inc. to $16.7 million from the previously disclosed $14 million, the company said in an exchange filing on Monday, September 28. The investment will be made through Natco Pharma's wholly owned subsidiaries Natco Pharma Inc. and Natco Pharma USA LLC through convertible promissory notes carrying an interest rate of 8% compounded annually.
其中，Natco Pharma将出资1370万美元，Natco Pharma USA将出资300万美元。预计这笔投资将在2026年10月31日前完成。此次投资是对Natco Pharma于8月25日发布的公告的更新；同时，公司还指出参与投资的子公司也发生了变化。
Natco Pharma will invest $13.7 million, while Natco Pharma USA will invest another $3 million. The investment is expected to be completed by October 31, 2026. The latest investment is an update to Natco Pharma's disclosure on August 25. The company also said there has been a change in the subsidiaries participating in the investment.
随着此次投资，Natco Pharma对eGenesis的总投资额将增至2470万美元，其中包括该公司在2024年已向eGenesis投入的800万美元。
Following the proposed investment, Natco Pharma's total investment in eGenesis will rise to $24.7 million, including the $8 million it invested in the US biotech in 2024.
那么，eGenesis公司到底是做什么的呢？eGenesis正在研发一种技术，旨在解决人体器官移植短缺的问题。该公司利用基因编辑技术对猪的器官进行改造，使其能够用于人体移植，从而降低器官排斥反应和病毒传播的风险。目前，eGenesis正在开展与肾脏移植、急性肝衰竭和心脏移植相关的研究项目。2024年3月，该公司因成功实施了全球首例“活体患者猪肾移植手术”而成为新闻焦点：该手术获得了美国食品药品监督管理局（FDA）的批准，属于FDA的“扩展访问计划”（Expanded Access Program）范畴。
What does eGenesis do?eGenesis is developing technology that could potentially help address the shortage of human organs available for transplantation. The company uses gene editing to modify pig organs so they can potentially be transplanted into humans while reducing the risk of rejection and viral transmission.eGenesis is currently developing programmes involving kidney transplantation, acute liver failure and heart transplantation. The company made headlines in March 2024 after conducting the world's first pig-kidney transplant in a living patient. The transplant was authorised by the US Food and Drug Administration under its Expanded Access pathway.
Natco Pharma表示，随后又有两名患者接受了猪肾移植手术。eGenesis目前是一家处于临床阶段、尚未产生收入的公司，正在开展涉及人体猪肾移植和猪肝灌流的临床试验。根据Natco Pharma披露的信息，此次投资旨在支持针对关键未满足医疗需求的新时代治疗项目。
Two additional patients subsequently received pig-kidney transplants, Natco Pharma said.eGenesis is currently a clinical-stage, pre-revenue company and is conducting clinical trials involving pig-kidney transplantation in humans and pig-liver perfusion. For Natco Pharma, the investment is aimed at backing new-age therapeutic programmes addressing critical unmet medical needs, according to the company's disclosure.
Natco Pharma批准127.9亿卢比的配股计划——查看日期、价格、配股比例及更多信息
Natco Pharma approves ₹1,279 crore rights issue - Check dates, price, entitlement ratio and more